GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemostemix Inc (TSXV:HEM) » Definitions » Other Long-Term Liabilities

Hemostemix (TSXV:HEM) Other Long-Term Liabilities : C$0.00 Mil (As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Hemostemix Other Long-Term Liabilities?

Hemostemix's other long-term liabilities for the quarter that ended in Sep. 2024 was C$0.00 Mil.

Hemostemix's quarterly other long-term liabilities increased from Dec. 2023 (C$-0.00 Mil) to Jun. 2024 (C$0.00 Mil) but then stayed the same from Jun. 2024 (C$0.00 Mil) to Sep. 2024 (C$0.00 Mil).

Hemostemix's annual other long-term liabilities declined from Dec. 2021 (C$0.00 Mil) to Dec. 2022 (C$-0.00 Mil) and declined from Dec. 2022 (C$-0.00 Mil) to Dec. 2023 (C$-0.00 Mil).

Hemostemix Other Long-Term Liabilities Historical Data

The historical data trend for Hemostemix's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemostemix Other Long-Term Liabilities Chart

Hemostemix Annual Data
Trend May14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hemostemix Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Sep24
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Hemostemix Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Hemostemix Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Hemostemix's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Hemostemix Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemostemix Inc (TSXV:HEM) » Definitions » Other Long-Term Liabilities
Comparable Companies
XCNQ:TRYP TSXV:XRTX XCNQ:CHGX XCNQ:DRUG XCNQ:BETR TSXV:KNE TSXV:RKV TSX:AEZS XCNQ:BLAB TSXV:RP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
HMTXF:USA 2VF0:Germany
Address
707 - 7th Avenue SouthWest, Suite 1150, Calgary, AB, CAN, T2P 3H6
Website
https://www.hemostemix.com
Hemostemix Inc is a biotechnology company. The company's principal business activity is developing, manufacturing, and commercializing blood-derived cell therapies for medical conditions. The Company's technology is a platform for developing autologous cell therapies to treat vascular diseases. The Company's clinical stage consists of ACP-01, autologous cell therapy for the treatment of critical limb ischemia.
Executives
Thomas Smeenk Director
Peter Alan Lacey Director
Loran Swanberg Director
Blake Wood 10% Security Holder
Ravi Jain Senior Officer

Hemostemix Headlines

No Headlines